Send to

Choose Destination
Transplantation. 2012 Sep 27;94(6):652-8.

Donor clara cell secretory protein polymorphism is a risk factor for bronchiolitis obliterans syndrome after lung transplantation.

Author information

Heart and Lung Transplant Unit, Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.



We hypothesized that a reduced potential for bronchiolar stem-cell (Clara cell)-related repair in the setting of an ever-present risk of small airway injury would increase the risk of bronchiolitis obliterans syndrome (BOS).


CCSP A38G gene polymorphism was assessed in both lung donors and recipients in a longitudinal study cohort of 63 consecutive lung transplant recipients (LTR) with a median follow-up of 493 days (range, 26-894). Clara cell secretory protein (CCSP) and interleukin 8 levels were assessed in the bronchoalveolar lavage and plasma at 1, 3, 6, and 12 months after transplantation. CCSP-positive cells were assessed in transbronchial biopsies at 1 and 3 months.


Of the 63 LTR, there were 5 early deaths (≤90 days, 8% [95% confidence interval, 4%-21%]), and 20 developed BOS (32%, [95% confidence interval, 21%-45%]). Donor but not recipient CCSP A38G polymorphism was associated with more risk of BOS (relative risk, 8.6 [2.2-33.5], P<0.0001) and decreased overall survival (log-rank test, P=0.011). Bronchoalveolar lavage CCSP and CCSP/interleukin 8 levels were low and decreasing early after transplantation in LTR who developed BOS (P=0.015). CCSP+ve cells in transbronchial biopsies increased at 3 months only in LTR who remained free of BOS (P=0.003).


Donor CCSP A38G polymorphism is associated with decreased CCSP levels early after lung transplantation and poor long-term outcomes.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center